At LenioBio, we believe every person should have the opportunity to live a healthy and productive life. And how do we do this? We develop robust, efficient and sustainable technologies to disrupt the way medicines and food are produced for those in need, wherever they are.
We are in the midst of an incredible journey and we are looking for passionate individuals to join us on this important mission. Do you want to be part of our journey? Then please keep reading!
At LenioBio GmbH, everything we do begins with our mission: to provide our customers with disruptive solutions to address their challenges easier, quicker, cheaper, better and safer.
Our ALiCE® technology scales with the pharmaceutical R&D process, from discovery to clinical trials/product testing and finally, to GMP-grade production, in the form of an end-to-end integrated production platform.
LenioBio aims to unlock the full potential of ALiCE® and will enable protein drugs to be brought to the market faster and at a lower cost.
About this job
The Head of R&D drives the R&D operations and projects. This position reports to the CSO of the company and is based in the Aachen labs. We seek for a strong leader dedicated to talent development and adapted to a highly dynamic environment. Location will change within in the next 2 years to a new building in the Dusseldorf-Neuss-Jülich-Aachen region.
We are looking for people that want to bring in their best, learn from the best and create the best. That does not mean you scored 180 on an IQ test. It means that you are an expert in your craft because you love what you do, you know you can become even better, and you are constantly looking for the boundary of the possible.
This job will suit you best if you
What we offer
Who we are
LenioBio is a biotech company that develops and markets a novel and proprietary protein production platform, ALiCE®, which enables protein-based therapeutics to become more accessible and affordable. LenioBio was founded in 2016 in Germany to broadly commercialize the ALiCE® platform, originally developed by DowDuPont and the Fraunhofer Institute IME.
In August 2019, LenioBio closed its Series A investment round with private investors and won a grant from the European Commission under the Horizon 2020 program/SME-2.
We aim to make them easy to remember, aspire to and act on.